Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New EU Consortium Focused on Discovery and Development of Novel Eye Therapeutics

Published: Monday, October 14, 2013
Last Updated: Monday, October 14, 2013
Bookmark and Share
Consortium supported by EU Seventh Framework Programme.

KalVista Pharmaceuticals is joining a group of academic and industry researchers to undertake a project known as ‘3D-NET’ (‘Drug Discovery and Development of Novel Eye Therapeutics’).

The four-year project seeks to enable the development of new drugs for the treatment of ocular disease associated with inflammation, neovascularisation, edema and degeneration, through the complementary capabilities of the partners.

The project will be funded through a €1.66 million Marie Curie Industry-Academia Pathways and Partnerships (IAPP) grant award from the EU Seventh Framework Programme (612218/3D-NET).

The consortium partners, in addition to KalVista, include leading researchers in front- and back-of-the-eye diseases, ocular disease models and synthetic chemistry at University College Dublin (Ireland), Universidad de Valladolid (Spain), RenaSci Ltd (Nottingham, UK) and Gadea Grupo Farmacéutico (Spain).

KalVista brings expertise in ocular diseases resulting from diabetes, such as diabetic macular edema, an extensive library of novel compounds already screened for activity in the eye, and proven capabilities in the development of drugs from target identification through to in vitro pharmacology and safety.

“We are delighted to be part of this EU project. The consortium brings a unique combination of skills and opportunities to overcome barriers to ocular drug discovery and development and advance new therapies for a range of eye diseases,” commented Andrew Crockett, KalVista CEO.

Crockett continued, “In addition, this project will provide KalVista with access to new ophthalmology projects and dovetails nicely with our internal programmes focused on intravitreal and oral plasma kallikrein inhibitors for DME. The intravitreal programme is advancing rapidly to the first in human trial, expected to start in early 2014, and we continue to progress our programme focused on novel oral drugs for DME.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Carbylan, KalVista Enter into Share Purchase Agreement
KalVista to become a wholly owned subsidiary of Carbylan, and KalVista shareholders to become majority owners of Carbylan upon the closing of the transaction.
Thursday, June 16, 2016
KalVista Announces Start of Clinical Development for Novel Treatment for DME
Phase I trial of plasma kallikrein inhibitor to be conducted in the US.
Thursday, August 21, 2014
KalVista Wins £2.4m Biomedical Catalyst Grant
Grant to further develop oral plasma kallikrein inhibitors as a treatment for diabetic macular edema.
Tuesday, November 06, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
New Discovery May Benefit Farmers Worldwide
Scientists have shown how a crop-microbe 'team' protect against fungal infection.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Protein Studies Discover Molecular Secrets
Two protein studies have mapped proteins that reveal the secrets to recycling carbon and healing cells.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!